Inès Vergnolle

Inès Vergnolle

Auto-generated profile, based on publicly available information

Inès Vergnolle

Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Laboratoire d’Hématologie, Toulouse, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ACAlban Canali
Alban Canali
IVInès Vergnolle
Inès Vergnolle
SBSarah Bertoli
Sarah Bertoli
LLLaetitia Largeaud
Laetitia Largeaud
MNMarie-Laure Nicolau
Marie-Laure Nicolau
FVFrancois Vergez
Francois Vergez
Purpose: Acute myeloid leukemias (AML) are clonal diseases that develop from leukemic stem cells (LSC) that carry an independent prognostic impact on the initial response to induction chemotherapy, demonstrating the clinical relevance of LSC abundance in AML. In 2018, the European LeukemiaNet published recommendations for the detection of measurable residual disease (Bulk MRD) and suggested the exploration of LSC MRD and the use of multiparametric displays. Experimental Design: We evaluated the performance of unsupervised clustering for the post-induction assessment of bulk and LSC MRD in 155 patients with AML who received intensive conventional chemotherapy treatment. Results: The median overall survival (OS) for Bulk+ MRD patients was 16.7 months and was not reached for negative patients (HR, 3.82; P < 0.0001). The median OS of LSC+ MRD patients was 25.0 months and not reached for negative patients (HR, 2.84; P = 0.001). Interestingly, 1-year (y) and 3-y OS were 60% and 39% in Bulk+, 91% and 52% in Bulk-LSC+ and 92% and 88% in Bulk-LSC−. Conclusions: In this study, we confirm the prognostic impact of post-induction multiparametric flow cytometry Bulk MRD in patients with AML. Focusing on LSCs, we identified a group of patients with negative Bulk MRD but positive LSC MRD (25.8% of our cohort) with an intermediate prognosis, demonstrating the interest of MRD analysis focusing on leukemic chemoresistant subpopulations.

16 March 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
IVInès Vergnolle
Inès Vergnolle
CDClaudia Douat-Beyries
Claudia Douat-Beyries
SBSerge Boulinguez
Serge Boulinguez
JRJean-Baptiste Rieu
Jean-Baptiste Rieu
JVjean-philippe vial
jean-philippe vial
FVFrancois Vergez
Francois Vergez
Sezary syndrome (SS) is a rare leukemic form of cutaneous T-cell lymphoma. Diagnosis mainly depends on flow cytometry, but results are not specific enough to be unequivocal. The difficulty in defining a single marker that could characterize Sezary cells may be the consequence of different pathological subtypes. In this study, we used multivariate flow cytometry analyses. We chose to investigate the expression of classical CD3, CD4, CD7, and CD26 and the new association of 2 markers CD158k and PD-1. We performed lymphocyte computational phenotypic analyses during diagnosis and follow-up of patients with SS to define new SS classes and improve the sensitivity of the diagnosis and the follow-up flow cytometry method. Three classes of SS, defined by different immunophenotypic profiles, CD158k+ SS, CD158k−PD-1+ SS, CD158k and PD-1 double-negative SS, showed different CD8+ and B-cell environments. Such a study could help to diagnose and define biological markers of susceptibility/resistance to treatment, including immunotherapy.

4 April 2024 in Leukemia
Verified
Journal Article
Open access
PDF file
CDCharles Dussiau
Charles Dussiau
TCThibault Comont
Thibault Comont
CKCamille Knosp
Camille Knosp
IVInès Vergnolle
Inès Vergnolle
CBClotilde Bravetti
Clotilde Bravetti
FVFrancois Vergez
Francois Vergez
Myelodysplastic neoplasms (MDS) are characterized by clonal evolution starting from the compartment of hematopoietic stem and progenitors cells (HSPCs), leading in some cases to leukemic transformation. We hypothesized that deciphering the diversity of the HSPCs compartment may allow for the early detection of an emergent sub-clone that drives disease progression. Deep analysis of HSPCs repartition by multiparametric flow cytometry revealed a strong disorder of the hematopoietic branching system in most patients at diagnosis with different phenotypic signatures closely related to specific MDS features. In two independent cohorts of 131 and 584 MDS, the HSPCs heterogeneity quantified through entropy calculation was decreased in 47% and 46% of cases, reflecting a more advanced state of the disease with deeper cytopenias, higher IPSS-R risk and accumulation of somatic mutations. We demonstrated that patients with lower-risk MDS and low CD34 + CD38+HSPCs entropy had an adverse outcome and that this parameter is as an independent predictive biomarker for progression free survival, leukemia free survival and overall survival. Analysis of HSPCs repartition at diagnosis represents therefore a very powerful tool to identify lower-risk MDS patients with a worse outcome and valuable for clinical decision-making, which could be fully integrated in the MDS diagnostic workflow.

4 August 2023 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
IVInès Vergnolle
Inès Vergnolle
TCTheo Ceccomarini
Theo Ceccomarini
ACAlban Canali
Alban Canali
JRJean‐Baptiste Rieu
Jean‐Baptiste Rieu
FVFrancois Vergez
Francois Vergez
Background: Mature B‐cell neoplasms are challenging to diagnose due to their heterogeneity and overlapping clinical and biological features. In this study, we present a new workflow strategy that leverages a large amount of flow cytometry data and an artificial intelligence approach to classify these neoplasms.Methods: By combining mathematical tools, such as classification algorithms and regression tree (CART) models, with biological expertise, we have developed a decision tree that accurately identifies mature B‐cell neoplasms. This includes chronic lymphocytic leukemia (CLL), for which cytometry has been extensively used, as well as other non‐CLL subtypes.Results: The decision tree is easy to use and proposes a diagnosis and classification of mature B‐cell neoplasms to the users. It can identify the majority of CLL cases using just three markers: CD5, CD43, and CD200.Conclusion: This approach has the potential to improve the accuracy and efficiency of mature B‐cell neoplasm diagnosis.

23 August 2023 in British Journal of Haematology
Verified
Journal Article
Closed access
MGMartin Gauthier
Martin Gauthier
DDDavid Dombrowski
David Dombrowski
IVInès Vergnolle
Inès Vergnolle
EKElias Kfoury
Elias Kfoury
FVFrancois Vergez
Francois Vergez
BDBarnabé Daniau
Barnabé Daniau

1 April 2023
Verified
Other
Open access
ACAlban Canali
Alban Canali
IVInès Vergnolle
Inès Vergnolle
SBSarah Bertoli
Sarah Bertoli
LLLaetitia Largeaud
Laetitia Largeaud
MNMarie-Laure Nicolau
Marie-Laure Nicolau
FVFrancois Vergez
Francois Vergez
Supplemental Table 1. Characteristics of AML patients. Supplemental Table 2. Flow cytometry antibodies. Supplemental Table 3. Multivariate Cox regression analysis of factors contributing to overall survival of AML patients. Supplemental Table 4. Multivariate Cox regression analysis of factors contributing to leukemia free survival of AML patients. Supplemental Table 5. Multivariate Cox regression analysis of factors contributing to overall survival of AML patients including the association of bulk and LSC MRD parameters. Supplemental Table 6. Multivariate Cox regression analysis of factors contributing to leukemia free survival of AML patients including the association of bulk and LSC MRD parameters.